Schiff R - Search Results

1

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.

Li L, Lin L, Veeraraghavan J, Hu Y, Wang X, Lee S, Tan Y, Schiff R, Wang XS. Li L, et al. Among authors: schiff r. Breast Cancer Res. 2020 Aug 8;22(1):84. doi: 10.1186/s13058-020-01325-3. Breast Cancer Res. 2020. PMID: 32771039 Free PMC article.

2

Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer.

Fuqua SA, Schiff R, Parra I, Friedrichs WE, Su JL, McKee DD, Slentz-Kesler K, Moore LB, Willson TM, Moore JT. Fuqua SA, et al. Among authors: schiff r. Cancer Res. 1999 Nov 1;59(21):5425-8. Cancer Res. 1999. PMID: 10554010

3

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Osborne CK, et al. Among authors: schiff r. J Natl Cancer Inst. 2003 Mar 5;95(5):353-61. doi: 10.1093/jnci/95.5.353. J Natl Cancer Inst. 2003. PMID: 12618500

4

Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters.

Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC. Fuqua SA, et al. Among authors: schiff r. Cancer Res. 2003 May 15;63(10):2434-9. Cancer Res. 2003. PMID: 12750263 Free PMC article.

5

Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs).

Schiff R, Chamness GC, Brown PH. Schiff R, et al. Breast Cancer Res. 2003;5(5):228-31. doi: 10.1186/bcr626. Epub 2003 Jul 28. Breast Cancer Res. 2003. PMID: 12927029 Free PMC article. Review.

6

Estrogen-mediated down-regulation of E-cadherin in breast cancer cells.

Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, Kang K, Hadsell DL, Behrens J, Lee AV. Oesterreich S, et al. Among authors: schiff r. Cancer Res. 2003 Sep 1;63(17):5203-8. Cancer Res. 2003. PMID: 14500345

7

Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.

Osborne CK, Schiff R. Osborne CK, et al. Among authors: schiff r. Breast. 2003 Dec;12(6):362-7. doi: 10.1016/s0960-9776(03)00137-1. Breast. 2003. PMID: 14659106 Review.

8

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Shou J, et al. Among authors: schiff r. J Natl Cancer Inst. 2004 Jun 16;96(12):926-35. doi: 10.1093/jnci/djh166. J Natl Cancer Inst. 2004. PMID: 15199112

9

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.

Osborne CK, Shou J, Massarweh S, Schiff R. Osborne CK, et al. Among authors: schiff r. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):865s-70s. Clin Cancer Res. 2005. PMID: 15701879 Review.

10

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Gutierrez MC, et al. Among authors: schiff r. J Clin Oncol. 2005 Apr 10;23(11):2469-76. doi: 10.1200/JCO.2005.01.172. Epub 2005 Mar 7. J Clin Oncol. 2005. PMID: 15753463

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

378 results

Search Page

Filters